[Therapeutic concept in Parkinson disease].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D005438:Fludrocortisone / Q000627:therapeutic use; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy; D007980:Levodopa / Q000627:therapeutic use; D008879:Midodrine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000523:psychology / Q000628:therapy*; D026741:Physical Therapy Modalities; D013788:Thalamus / Q000601:surgery; D014202:Tremor / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000929:Antidepressive Agents, Tricyclic; D010276:Parasympatholytics; D001569:Benzodiazepines; D001971:Bromocriptine; D007980:Levodopa; D008879:Midodrine; D000547:Amantadine; D005438:Fludrocortisone
Therapiekonzept bei Parkinsonscher Krankheit.